Rising importance of patient-reported outcomes

摘要

The Article by Basch and colleagues1 in this month's The Lancet Oncology takes another step in the growing movement in clinical trial research in oncology towards the incorporation of patient-reported outcomes (PROs). Basch and co-workers adapt the US National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) for use by patients rather than by clinicians. The aim of the researchers was to describe the commonalities and discrepancies between adverse event grading by patients and by clinicians.